Aromatase inhibitors--where are we now?
作者信息
Miller W R
机构信息
University Department of Clinical Oncology, Western General Hospital, Edinburgh, UK.
出版信息
Br J Cancer. 1996 Feb;73(4):415-7. doi: 10.1038/bjc.1996.73.
Abstract
摘要
相似文献
1
Aromatase inhibitors--where are we now?
Br J Cancer. 1996 Feb;73(4):415-7. doi: 10.1038/bjc.1996.73.
2
A better medication for treating breast cancer?
Johns Hopkins Med Lett Health After 50. 2002 May;14(3):3.
3
Aromatase inhibitors and breast cancer.
Cancer Treat Rev. 1997 May;23(3):171-87. doi: 10.1016/s0305-7372(97)90037-2.
4
[Aromatase inhibitors: a review of clinical trials].
Bull Cancer. 2000 Dec;87 Spec No:31-39.
5
[Aromatase inhibitors].
Bull Cancer. 2000 Dec;87 Spec No:5.
6
Aromatase inhibitors for hormonal therapy of early-stage breast cancer.
Curr Opin Investig Drugs. 2004 Jun;5(6):605-10.
7
New endocrine approaches in the treatment of breast cancer.
Biomed Pharmacother. 1998;52(3):122-32. doi: 10.1016/S0753-3322(98)80090-5.
8
[Aromatase inhibitors in the treatment of breast cancer].
Rev Med Suisse Romande. 2000 Jun;120(6):495-500.
9
Tamoxifen vs the aromatase inhibitors: news from San Antonio, 2001.
Cancer Control. 2001 Nov-Dec;8(6):478-9. doi: 10.1177/107327480100800601.
10
Breast cancer face-off.
US News World Rep. 2002 Jun 3;132(19):54.
引用本文的文献
1
Elevated incidence of fractures in women with invasive breast cancer.
Osteoporos Int. 2016 Feb;27(2):499-507. doi: 10.1007/s00198-015-3246-3. Epub 2015 Aug 21.
2
Estrogen biosynthesis and action in ovarian cancer.
Front Endocrinol (Lausanne). 2014 Nov 12;5:192. doi: 10.3389/fendo.2014.00192. eCollection 2014.
3
Inhibition of aromatase activity and expression in MCF-7 cells by the chemopreventive retinoid N-(4-hydroxy-phenyl)-retinamide.
Br J Cancer. 2000 Aug;83(3):333-7. doi: 10.1054/bjoc.2000.1269.
本文引用的文献
1
Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
Clin Cancer Res. 1995 Mar;1(3):287-94.
2
The effects of long term fadrozole hydrochloride treatment in patients with advanced stage breast cancer.
J Steroid Biochem Mol Biol. 1993 Mar;44(4-6):683-5. doi: 10.1016/0960-0760(93)90282-2.
3
Estrogen and androgen receptor mediated stimulation and inhibition of proliferation by androst-5-ene-3 beta,17 beta-diol in human mammary cancer cells.
J Steroid Biochem Mol Biol. 1993 Nov;46(5):597-603. doi: 10.1016/0960-0760(93)90187-2.
4
Recent advances in biochemical markers of bone turnover.
Clin Chem. 1994 Nov;40(11 Pt 1):1994-5.
5
Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer.
Cancer Res. 1994 Nov 15;54(22):5875-81.
6
Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients.
Breast Cancer Res Treat. 1994;30(1):95-102. doi: 10.1007/BF00682744.
7
8
Endocrine changes with the aromatase inhibitor fadrozole hydrochloride in breast cancer.
Eur J Cancer. 1994;30A(10):1453-8. doi: 10.1016/0959-8049(94)00281-9.
9
Aromatase inhibitor development for treatment of breast cancer.
Breast Cancer Res Treat. 1995;33(1):19-26. doi: 10.1007/BF00666067.
10
Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer.
Cancer. 1995 Apr 15;75(8):2132-8. doi: 10.1002/1097-0142(19950415)75:8<2132::aid-cncr2820750816>3.0.co;2-u.
Zotero 插件